Quest for the right Drug

|
עמוד הבית / סימוביל 10 מ"ג / מידע מעלון לרופא

סימוביל 10 מ"ג SIMOVIL 10 MG (SIMVASTATIN)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

פומי : PER OS

צורת מינון:

טבליה : TABLETS

Interactions : אינטראקציות

7     DRUG INTERACTIONS
7.1     Strong CYP3A4 Inhibitors, cyclosporine, or danazol
Strong CYP3A4 inhibitors: Simvastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of CYP3A4. Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.
Elevated plasma levels of HMG-CoA reductase inhibitory activity increases the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin. [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).] Concomitant use of drugs labeled as having a strong inhibitory effect on CYP3A4 is contraindicated [see Contraindications (4)]. If treatment with itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin must be suspended during the course of treatment.
Cyclosporine or Danazol: The risk of myopathy, including rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol. Therefore, concomitant use of these drugs is contraindicated.
[see Contraindications (4), Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].
7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone
Gemfibrozil: Contraindicated with simvastatin [see Contraindications (4) and Warnings and Precautions (5.1)].
Other fibrates: Caution should be used when prescribing with simvastatin [see Warnings and Precautions (5.1)].
7.3 Fusidic Acid
The risk of myopathy/rhabdomyolysis may be increased by concomitant administration of fusidic acid [see Warnings and Precautions (5.1)].
7.4     Amiodarone, Dronedarone, Ranolazine, or Calcium Channel Blockers The risk of myopathy, including rhabdomyolysis, is increased by concomitant administration of amiodarone, dronedarone, ranolazine, or calcium channel blockers such as verapamil, diltiazem, or amlodipine [see Dosage and Administration (2.3) and Warnings and Precautions (5.1), and Table 3 in Clinical Pharmacology (12.3)].
7.5 Lomitapide:
The risk of myopathy/rhabdomyolysis may be increased by concomitant administration of lomitapide [see Warnings and Precautions (5.1)].and Table 3 in Clinical Pharmacology (12.3)].
7.6 Moderate Inhibitors of CYP3A4:
Patients taking other medicines labeled as having a moderate inhibitory effect on CYP3A4 concomitantly with simvastatin, particularly higher simvastatin doses, may have an increased risk of myopathy [see Warnings and Precautions (5.1)].


7.7 Inhibitors of the Transport Protein OATP1B1: Simvastatin acid is a substrate of the transport protein OATP1B1. Concomitant administration of medicinal products that are inhibitors of the transport protein OATP1B1 may lead to increased plasma concentrations of simvastatin acid and an increased risk of myopathy (see Contraindications; Precautions, Myopathy/Rabdomyalysis).
7.8     Niacin
Cases of myopathy/rhabdomyolysis have been observed with simvastatin coadministered with lipid-modifying doses (≥1 g/day niacin) of niacin-containing products. In particular, caution should be used when treating Chinese patients with simvastatin doses exceeding 20 mg/day coadministered with lipid-modifying doses of niacin-containing products. Because the risk for myopathy is dose-related, Chinese patients should not receive simvastatin 80 mg coadministered with lipid-modifying doses of niacin-containing products. [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).] 7.9     Digoxin
In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma. Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].
7.10 Coumarin Anticoagulants
In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively. With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly. In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.
Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants. If the dose of simvastatin is changed or discontinued, the same procedure should be repeated. Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.
7.11 Colchicine
Cases of myopathy, including rhabdomyolysis, have been reported with simvastatin coadministered with colchicine, and caution should be exercised when prescribing simvastatin with colchicine.

שימוש לפי פנקס קופ''ח כללית 1994 Adjunct to dietary therapy to decrease elevated serum total and LDL cholesterol concentrations in primary hypercholesterolemia (types IIa and IIb) when the response to diet and other nonpharmacological methods has been inadequate. יירשם לפי פרוטוקול טיפולי מחייב
תאריך הכללה מקורי בסל 01/01/1995
הגבלות תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת

רישום

127 53 26694 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

04.03.15 - עלון לרופא

עלון מידע לצרכן

25.05.15 - עלון לצרכן אנגלית 25.05.15 - עלון לצרכן עברית 25.05.15 - עלון לצרכן ערבית 01.01.15 - החמרה לעלון

לתרופה במאגר משרד הבריאות

סימוביל 10 מ"ג

קישורים נוספים

RxList WebMD Drugs.com